Starbucks to drop employee coverage for GLP-1 weight-loss drugs from October
Starbucks has announced it will stop covering GLP-1 weight-loss medications for its employees beginning October, citing rising healthcare costs. GLP-1 drugs, originally developed to treat diabetes, have gained widespread use as obesity treatments in recent years. The move reflects a growing trend among US employers scaling back benefits related to these expensive medications. Other organizations, including Allina Health and PwC, have similarly revised their coverage policies. In contrast, Bank of America continues to support GLP-1 coverage, considering it a worthwhile investment in employee health.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.
Discussion (0)
Log in to join the discussion and vote.
Log in